Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients

Diletta Fontana, PhD, Daniele Ramazzotti, PhD, Andrea Aroldi, MD, Antonio Niro, MS, Luca Massimino, PhD, Delphine Rea, MD, Fabio Stagno, MD, Bruno Martino, MD, Leonardo Campiotti, MD, Giovanni Caocci, MD, Elena Maria Elli, MD, Monica Fumagalli, MD, Fabio Ciceri, MD, Rocco Piazza, MD PhD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1714.

https://doi.org/10.1182/blood-2019-126467

Published: 2019

Journal Articles

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Pinkal Desai, MDMPH, Niamh Savage, BA, Spencer Krichevsky, BS, Tania Curcio, Sangmin Lee, MD, Michael B. Samuel, MD, Ellen K. Ritchie, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1666.

https://doi.org/10.1182/blood-2019-127663

Published: 2019

Journal Articles

Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients

Blood (2019) 134 (Supplement_1): 3005.

https://doi.org/10.1182/blood-2019-124115

Published: 2019

Journal Articles

New Germline Syndrome Discovery: Heterozygous CSF3R Mutations May Predispose to Myeloid and Lymphoid Malignancies

Amy M Trottier, MDBSc,MSc, Ira L Kraft, MD, Lawrence J Druhan, PhD, Amanda Lance, MS, Belinda R Avalos, MD, Lucy A Godley, MD PhD

Blood (2019) 134 (Supplement_1): 2543.

https://doi.org/10.1182/blood-2019-129492

Published: 2019

Journal Articles

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis

Blood (2019) 134 (11): 867–879.

https://doi.org/10.1182/blood.2019000611

Published: 2019

Includes: Supplemental data

Journal Articles

A MAFB Associated Regulatory Network Distinguishes CMML from Other MDS/MPN Overlap Entities

Wencke Walter, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD, Manja Meggendorfer, PhD

Blood (2018) 132 (Supplement 1): 3890.

https://doi.org/10.1182/blood-2018-99-115838

Published: 2018

Journal Articles

FOS Expression Distinguishes Two Groups of Atypical CML (aCML) Allowing Targeted Therapy

Manja Meggendorfer, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2018) 132 (Supplement 1): 3893.

https://doi.org/10.1182/blood-2018-99-111832

Published: 2018

Journal Articles

HMGA2 mRNA Expression in Patients with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

Keiji Minakawa, Koki Ueda, MD PhD, Akiko Shichishima, MD PhD, Hiroshi Ohkawara, MD PhD, Kazuei Ogawa, MD PhD, Takayuki Ikezoe, MD PhD, Yayoi Shikama, MD PhD, Kenneth E Nollet, MD PhD, Kazuhiko Ikeda, MD PhD

Blood (2018) 132 (Supplement 1): 4384.

https://doi.org/10.1182/blood-2018-99-114399

Published: 2018

Journal Articles

Atypical Chronic Myeloid Leukemia

Chandralekha Ashangari, MD, Praveen K. Tumula, MD

Blood (2018) 132 (Supplement 1): 5455.

https://doi.org/10.1182/blood-2018-99-110189

Published: 2018

Journal Articles

Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice

Vasily Shuvaev, MD, Karina Krutikova, MD, Svetlana Menshakova, MD, Natalya Kalinova, MD, Irina Martynkevich, MD PhD, Lyubov Polushkina, MD, Elena Belyakova, MD, Yury Krivolapov, MD PhD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2018-99-114885

Published: 2018

Journal Articles

Genotypic Representation of Myelodysplastic/Myeloproliferative Neoplasms in Nrg, Nrg-3GS and Srg-W41 Mice with Transgenic Expression of Human Cytokines

Hein Than, MD FRCPath, MRCP, Naoto Nakamichi, MD PhD, Anthony D. Pomicter, MS, John O'Shea, PhD, Orlando Antelope, Thomas O'Hare, PhD, Connie J. Eaves, PhD, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 2038.

https://doi.org/10.1182/blood-2018-99-111728

Published: 2018

Journal Articles

Checkpoint Inhibition in CSF3R Mutated Chronic Neutrophilic Leukemia

Stefanie Kreutmair, MD, Teresa Poggio, Chuanjiang Yu, Sivahari Prasad Gorantla, Khalid Shoumariyeh, Dietmar Pfeifer, Michael Lubbert, MD PhD, Karsten Spiekermann, MD, Robert Zeiser, MD, Justus Duyster, Prof., Anna Lena Illert, MD

Blood (2018) 132 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2018-99-113847

Published: 2018

Journal Articles

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Kim-Hien Dao, DO,PhD, Robert H. Collins, MD, Jorge E. Cortes, MD, Michael W. Deininger, MD PhD, Brian J. Druker, MD, Jason R. Gotlib, MDMS, Tara Alyson Macey, PhD, Stephen T Oh, MD PhD, Jeffrey W. Tyner, PhD, Elliott F. Winton, MD

Blood (2018) 132 (Supplement 1): 350.

https://doi.org/10.1182/blood-2018-99-119476

Published: 2018

Journal Articles

Genetic Mutation Spectrum in a Cohort of Chinese MDS/MPN Patients Revealed By Targeted Next Generation Sequencing

Yujiao Jia, MD, Li Qin, PhD, Donglei Zhang, PhD, Long Chen, MD, Jing Li, MD, KunYuan Kou, MD, Hao Tan, B.S., Kun Ru, MD PhD

Blood (2017) 130 (Supplement 1): 5308.

https://doi.org/10.1182/blood.V130.Suppl_1.5308.5308

Published: 2017

Journal Articles

C-Terminal BRE Overexpression in 11q23-Rearranged and t(8;16) Acute Myeloid Leukemia Is Caused By Intragenic Transcription Initiation

Blood (2017) 130 (Supplement 1): 3810.

https://doi.org/10.1182/blood.V130.Suppl_1.3810.3810

Published: 2017

Journal Articles

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Timothy S Pardee, MD PhD, Scott Isom, M.S., Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2017) 130 (Supplement 1): 2626.

https://doi.org/10.1182/blood.V130.Suppl_1.2626.2626

Published: 2017

Journal Articles

Identification of SETBP1 As an Epigenetic Hub Protein That Induces the Transcription of a Network of Development-Related Genes

Blood (2017) 130 (Supplement 1): 4980.

https://doi.org/10.1182/blood.V130.Suppl_1.4980.4980

Published: 2017

Journal Articles

How I treat atypical chronic myeloid leukemia

Jason Gotlib

Blood (2017) 129 (7): 838–845.

https://doi.org/10.1182/blood-2016-08-693630

Published: 2017

Journal Articles

Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

Naval G. Daver, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Prithviraj Bose, MD, Lingsha Zhou, Sherry Pierce, BSN, BA, Stephanie Van Derbur, Carla Kay Tuttle, RN, Gautam Borthakur, MD, Zeev Estrov, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 4246.

https://doi.org/10.1182/blood.V128.22.4246.4246

Published: 2016

Journal Articles

Recurrent Pathogenic Cyclin D2 Mutations in Myeloid Malignancies

Vishesh Khanna, BS, Christopher A. Eide, Cristina E. Tognon, Julia E. Maxson, PhD, Beth Wilmot, Daniel Bottomly, Shannon K. McWeeney, Brian J. Druker, MD, Jeffrey W. Tyner

Blood (2016) 128 (22): 2734.

https://doi.org/10.1182/blood.V128.22.2734.2734

Published: 2016

NARROW

Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients

New Germline Syndrome Discovery: Heterozygous CSF3R Mutations May Predispose to Myeloid and Lymphoid Malignancies

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis

A MAFB Associated Regulatory Network Distinguishes CMML from Other MDS/MPN Overlap Entities

FOS Expression Distinguishes Two Groups of Atypical CML (aCML) Allowing Targeted Therapy

HMGA2 mRNA Expression in Patients with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

Atypical Chronic Myeloid Leukemia

Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice

Genotypic Representation of Myelodysplastic/Myeloproliferative Neoplasms in Nrg, Nrg-3GS and Srg-W41 Mice with Transgenic Expression of Human Cytokines

Checkpoint Inhibition in CSF3R Mutated Chronic Neutrophilic Leukemia

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Genetic Mutation Spectrum in a Cohort of Chinese MDS/MPN Patients Revealed By Targeted Next Generation Sequencing

C-Terminal BRE Overexpression in 11q23-Rearranged and t(8;16) Acute Myeloid Leukemia Is Caused By Intragenic Transcription Initiation

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Identification of SETBP1 As an Epigenetic Hub Protein That Induces the Transcription of a Network of Development-Related Genes

How I treat atypical chronic myeloid leukemia

Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

Recurrent Pathogenic Cyclin D2 Mutations in Myeloid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only